Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center

Completed · Phase 1

Conditions studied: Immune System Diseases

In brief

The long-term goal of the investigators study is to develop a better and safer treatment for, and to potentially cure patients with single or multiple food allergies. The investigators hypothesize that the application of this protocol will allow patients with severe and single or multiple food allergies to be safely and rapidly desensitized.

Key facts

Study ID
NCT01510626
Run by
Stanford University
People needed
35
Starts
2011-11-01
Expected to finish
2015-12-01
Last updated by the study team
2015-12-10

Who can join

Age: 4 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.